NU Hospital Group-Vastra Gotalandsregionen — Clinical Trial Site

22 Registered trials

13 Currently recruiting

Organisation

NU Hospital Group-Vastra Gotalandsregionen

Location

Trollhattan, Sweden

Identifier

ORG-100042604

Address

Larketorpsvagen, 461 85, Sweden

Departments

9501: Uddevalla Hospital, Hematologmottagningen, 54180 Uddevalla
Barnmottagningen NÄL
Department of Hematology
Hematologen
Hematology
Infektionskliniken
Infektionskliniken, NÄL
Kardiologi avdelning
Medicinkliniken, Njurmedicin
NÄL Hospital, Department of obstetrics and gynecology, Lärketorpsvägen, 461 73 Trollhättan
NÄL, Clinical Trial Center, Endocrinology/Diabetes, Larketorpsvagen 20, 461 73 Trollhattan
NÄL, Diabetesmottagningen plan 5, Uddevalla sjukhus, Fjällvägen 9, 45153 Uddevalla
NÄL, Öron-, Näs-, och Halskliniken, Lärketorpsvägen 20, 261 73 Trollhättan
of Urology
Pediatrics
Surgical department
Uddevalla hospital, Clinical Trial Center, Endocrinology/Diabetes, Fjällvägen 9, 451 53 Uddevalla
Uddevalla Hospital, Department of Medicine, Section of Hematology, Fjällvagen 9, 451 80 Uddevalla
Uddevalla Hospital, Dept. of Hematology
Uddevalla Hospital, Fjällvägen 9, 45153 Uddevalla, hematology dept
Uddevalla sjukhus, Hematologmottagningen, NU-sjukvården, Fjällvägen 9, 451 80 Uddevalla
Uddevalla Sjukhus, Infektionskliniken

Clinical trials at this site (22)

Search interface

ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signa… Pending

2024-513778-23-00 Colon and rectal cancer tumor stage II-III, tumor with 5
Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) Pending

2025-523476-23-00 Tick-Borne Encephalitis (TBE) 4
Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer Recruiting

2022-502221-18-00 Recurrent non-muscle invasive bladder cancer 6 2025-05-26
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment Recruiting

2025-524022-18-00 Multiple myeloma 4 2026-05-22
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1… Recruiting

2023-508196-36-00 Follicular lymphoma 4 2025-05-27
A clinical phase IV trial to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in … Recruiting

2024-511182-10-01 Pediatric cancer 6 2025-05-22
COMeBAC- COMparison between Bensypenicillin And Cloxacillin treatment in PSSA Recruiting

2023-506860-15-00 Staphylococcus aureus bacteraemia 6 2024-06-11
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
Alternative antibiotics to multidrug-resistant UTIs Recruiting

2024-513294-41-00 Urinary tract infection and/or bacteremia caused by ext 6 2023-04-17
SACK Recruiting

2022-501600-10-00 Atrial fibrillation and Chronic Kidney Disease stage 5 5 2023-02-07
A randomized double-blind clinical trial comparing Hypochlorous Acid and Polyhexamethylene biguanide in treating diabetic foot ulcers Recruiting

2024-512612-22-00 Diabetic Foot Ulcer 5 2021-12-09
OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting

2023-507164-39-00 Induction of labour 6 2021-12-01
Optimized pharmacologic treatment for broken heart (takotsubo) syndrome Recruiting

2022-501874-21-00 Takotsubo syndrome 6 2020-12-15
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2024-06-17
A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o… Ended

2023-504277-20-00 Eosinophilic esophagitis (EoE) is a rare, chronic infla 5 2023-01-30
Ixekizumab Diabetes Intervention Trial (I-DIT) Ended

2023-508588-58-00 Diabetes type 1 4 2022-10-25
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended

2023-509864-96-00 Mantle Cell Lymphoma (MCL) 4 2021-12-07
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended

2024-517321-99-00 Myeloma multiplex 4 2016-08-01
An open label, multi-center, Phase IV rollover protocol to evaluate long term safety data Ended

2024-515283-31-00 This study is designed to accept patients with varied d 6 2015-07-30
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Ended

2024-515892-36-00 C3 glomerulopathy 4 2020-01-01
ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma … Ended

2022-501138-49-00 Follicular Lymphoma 4